Leveraging Blockchain Technology for Informed Consent Process and Patient Engagement in a Clinical Trial Pilot
DOI:
https://doi.org/10.30953/bhty.v4.182Keywords:
blockchain technology, clinical trials, healthcare and medical research, informed consent, Hyperledger FabricAbstract
Objective: Despite the implementation of quality assurance procedures, current clinical trial management processes are time-consuming, costly, and often susceptible to error. This can result in limited trust, transparency, and process inefficiencies, without true patient empowerment. The objective of this study was to determine whether blockchain technology could enforce trust, transparency, and patient empowerment in the clinical trial data management process, while reducing trial cost.
Design: In this proof of concept pilot, we deployed a Hyperledger Fabric-based blockchain system in an active clinical trial setting to assess the impact of blockchain technology on mean monitoring visit time and cost, non-compliances, and user experience. Using a parallel study design, we compared differences between blockchain technology and standard methodology.
Results: A total of 12 trial participants, seven study coordinators and three clinical research associates across five sites participated in the pilot. Blockchain technology significantly reduces total mean monitoring visit time and cost versus standard trial management (475 to 7 min; P = 0.001; €722 to €10; P = 0.001 per participant/visit, respectively), while enhancing patient trust, transparency, and empowerment in 91, 82 and 63% of the patients, respectively. No difference in non-compliances as a marker of trial quality was detected.
Conclusion: Blockchain technology holds promise to improve patient-centricity and to reduce trial cost compared to conventional clinical trial management. The ability of this technology to improve trial quality warrants further investigation.
Downloads
References
Gaba P, Bhatt DL. The COVID-19 pandemic: a catalyst to improve clinical trials. Nat Rev Cardiol 2020 Nov; 17(11): 673–5. doi: 10.1038/s41569-020-00439-7
Inspectorate Program. Annual inspection summary report 2015–2016 [Internet]. Health Canada. Available from: https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-health-products/compliance-enforcement/inspectorate-program-annual-inspection-summary-report-2015-2016/aisr-2015-2016-eng.pdf [updated 7 November 2017, cited 5 February 2021].
Annual report of the good clinical practice inspectors working group 2016 [Internet]. European Medicines Agency. June 15, 2017. Available from: https://www.ema.europa.eu/en/documents/report/annual-report-good-clinical-practice-inspectors-working-group-2016_en.pdf [cited 16 March 2021].
Research and analysis: good clinical practice inspection metrics. Good clinical practice inspection metrics for 2015 to 2016 [Internet]. Medicines and Healthcare products Regulatory Agency. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment
_data/file/631254/GCP_INSPECTIONS_METRICS_2015-2016__FINAL_21-07-17_.pdf [updated 15 February 2021, cited 21 March 2021].
Guidance for industry. Oversight of clinical investigations – a risk-based approach to monitoring [Internet]. Food and Drug Administration (FDA). August 2013. Available from: https://www.fda.gov/media/116754/download [cited 23 February 2021].
Baigent C, Harrell FE, Buyse M, Emberson JR, Altman DG. Ensuring trial validity by data quality assurance and diversification of monitoring methods. Clin Trials 2008 Feb; 5(1): 49–55. doi: 10.1177/1740774507087554
Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2) [Internet]. International Council for Harmonisation. November 9, 2016. Available from: https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf [cited 11 March 2021].
WMA Declaration of Helsinki – ethical principles for medical research involving human subjects [Internet]. World Medical Association; July 9, 2018. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ [cited 11 March 2021].
Inspectional Observation Data Set FY 2016 [Internet]. U.S. Food and Drug Administration. November 24, 2020. Available from: https://www.fda.gov/media/101615/download [cited 16 March 2021].
Nugent T, Upton D, Cimpoesu M. Improving data transparency in clinical trials using blockchain smart contracts. F1000Res 2016; 5: 2541. doi: 10.12688/f1000research.9756.1
Omar IA, Jayaraman R, Salah K, Simsekler MC, Yaqoob I, Ellahham S. Ensuring protocol compliance and data transparency in clinical trials using blockchain smart contracts. BMC Med Res Methodol 2020 Dec; 20(1): 1–7. doi: 10.1186/s12874-020-01109-5
Benchoufi M, Ravaud P. Blockchain technology for improving clinical research quality. Trials 2017 Dec; 18(1): 1–5. doi: 10.1186/s13063-017-2035-z
Choudhury O, Sarker H, Rudolph N, Foreman M, Fay N, Dhuliawala M, et al. Enforcing human subject regulations using blockchain and smart contracts. Blockchain Healthc Today 2018 Mar 23; 1: 1–4. doi: 10.30953/bhty.v1.10
Omar IA, Jayaraman R, Salah K, Yaqoob I, Ellahham S. Applications of blockchain technology in clinical trials: review and open challenges. Arab J Sci Eng 2020 Oct 14: 1–5. doi: 10.1007/s13369-020-04989-3
Maslove DM, Klein J, Brohman K, Martin P. Using blockchain technology to manage clinical trials data: a proof-of-concept study. JMIR Med Inform 2018; 6(4): e11949. doi: 10.2196/11949
Elmer M, Florek C, Gabryelski L, Greene A, Inglis AM, Johnson KL, et al. Amplifying the voice of the patient in clinical research: development of toolkits for use in designing and conducting patient-centered clinical studies. Ther Innov Regul Sci 2020 Nov; 54(6): 1489–500. doi: 10.1007/s43441-020-00176-6
Branch E. Ways to lower costs of clinical trials and how CROs help [Internet]. Am Pharm Rev 2016. Available from: https://www.americanpharmaceuticalreview.com/Featured-Articles/185929-Ways-to-Lower-Costs-of-Clinical-Trials-and-How-CROs-Help/ [cited 5 February 2021].
Benchoufi M, Porcher R, Ravaud P. Blockchain protocols in clinical trials: transparency and traceability of consent. F1000Res 2017; 6: 66. doi: 10.12688/f1000research.10531.5
Wong DR, Bhattacharya S, Butte AJ. Prototype of running clinical trials in an untrustworthy environment using blockchain. Nat Commun 2019 Feb 22; 10(1): 1–8. doi: 10.1038/s41467-019-08874-y
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Baldwin C. Mak, PhD, Bryan T. Addeman, BSc, MBA, Jia Chen, PhD, Kim A. Papp, MD, PhD, FRCPC, FAAD, Melinda J. Gooderham, MSc, MD, FRCPC, Lyn C. Guenther, MD, FRCPC, FAAD, Yi Liu, PhD, Uli C. Broedl, MD, Marianne E. Logger, BSc
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain copyright of their work, with first publication rights granted to Blockchain in Healthcare Today (BHTY). Read the full Copyright Statement.
